• PARP-inhibition reprograms macrophages toward an anti-tumor phenotype 

      Wang, Lin; Wang, Dan; Sonzogni, Olmo; Ke, Shizhong; Wang, Qi; Thavamani, Abhishek; Batalini, Felipe; Stopka, Sylwia A.; Regan, Michael S.; Vandal, Steven; Tian, Shengya; Pinto, Jocelin; Cyr, Andrew M.; Bret-Mounet, Vanessa C.; Baquer, Gerard; Eikesdal, Hans Petter; Yuan, Min; Asara, John M.; Heng, Yujing J.; Bai, Peter; Agar, Nathalie Y.R.; Wulf, Gerburg M. (Journal article; Peer reviewed, 2022)
      Poly(ADP)ribosylation inhibitors (PARPis) are toxic to cancer cells with homologous recombination (HR) deficiency but not to HR-proficient cells in the tumor microenvironment (TME), including tumor-associated macrophages ...